Forian (NASDAQ:FORA) Receives Buy Rating from Roth Mkm

Forian (NASDAQ:FORA)‘s stock had its “buy” rating restated by research analysts at Roth Mkm in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $5.00 price objective on the stock. Roth Mkm’s target price indicates a potential upside of 148.76% from the stock’s current price.

Forian Stock Performance

FORA stock traded down $0.03 on Thursday, reaching $2.01. The company’s stock had a trading volume of 1,538 shares, compared to its average volume of 15,665. The firm has a market cap of $62.53 million, a PE ratio of 40.20 and a beta of 1.09. The business has a fifty day simple moving average of $2.15 and a two-hundred day simple moving average of $2.44. Forian has a 12-month low of $2.00 and a 12-month high of $4.15.

Forian (NASDAQ:FORA) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.06). The business had revenue of $4.78 million for the quarter, compared to analyst estimates of $5.26 million. During the same period in the previous year, the business earned ($0.03) EPS.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Elser Financial Planning Inc purchased a new position in shares of Forian in the 2nd quarter valued at approximately $1,885,000. Canton Hathaway LLC raised its holdings in Forian by 2.3% in the third quarter. Canton Hathaway LLC now owns 269,650 shares of the company’s stock worth $582,000 after purchasing an additional 6,125 shares in the last quarter. Finally, Caprock Group LLC purchased a new position in Forian during the second quarter valued at $230,000. Hedge funds and other institutional investors own 19.25% of the company’s stock.

About Forian

Forian Inc provides a suite of data management capabilities, and information and analytics solutions to optimize and measure operational, clinical, and financial performance for customers in the healthcare and related industries. It develops commercial, real world evidence (RWE), and market access solutions and proprietary data-driven insights, as well as offers data management solutions.